Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
May 15 2024 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
|
|
|
SEC
FILE NUMBER |
|
FORM
12b-25 |
000-53223 |
|
|
|
|
NOTIFICATION OF LATE
FILING |
CUSIP
NUMBER |
|
|
570372102 |
(Check one): |
☐
Form 10-K |
☐ Form 20-F |
☐ Form 11-K |
☒ Form 10-Q |
☐
Form 10-D |
☐
Form N-CEN |
|
☐ Form N-CSR |
|
|
|
|
|
|
For Period Ended: March 31, 2024 |
|
☐ |
Transition Report on Form 10-K |
|
☐ |
Transition Report on Form 20-F |
|
☐ |
Transition Report on Form 11-K |
|
☐ |
Transition Report on Form 10-Q |
|
☐ |
For the Transition Period Ended: _______________________________________________ |
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
Marizyme,
Inc. |
Full Name of Registrant |
|
N/A |
Former Name if Applicable |
|
555
Heritage Drive, Suite 205 |
Address of Principal Executive
Office (Street and Number) |
|
Jupiter,
Florida 33458 |
City, State and Zip Code |
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
(a) |
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
|
(c) |
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11- K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could
not be filed within the prescribed time period.
The
Registrant is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Form 10-Q”)
because of unanticipated delays in the completion of its financial statements and related portions of the Form 10-Q, which delays
could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 under the
Securities Exchange Act of 1934, as amended, the Registrant anticipates filing its Form 10-Q no later than five calendar days
following the prescribed due date.
PART
IV — OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification.
David
Barthel |
|
561 |
|
935-9955 |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). Yes ☒ No ☐
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Marizyme,
Inc. |
(Name
of Registrant as Specified in Charter) |
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
May 15, 2024 |
By: |
/s/
David Barthel |
|
|
David
Barthel |
|
|
Chief
Executive Officer |
Marizyme (QB) (USOTC:MRZM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Marizyme (QB) (USOTC:MRZM)
Historical Stock Chart
From Nov 2023 to Nov 2024